User menu

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Bibliographic reference Chanan-Khan, Asher ; Cramer, Paula ; Demirkan, Fatih ; Fraser, Graeme ; Silva, Rodrigo Santucci ; et. al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.. In: The Lancet Oncology, Vol. 17, no.2, p. 200-211 (2016)
Permanent URL http://hdl.handle.net/2078.1/183418